Enlivex Ltd. Receives Nasdaq Minimum Bid Price Deficiency Notice
On May 15, 2026, Enlivex Ltd. received a deficiency notice from the Nasdaq Stock Market LLC indicating that the company is no longer in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The notice was triggered because the closing bid price of Enlivex's ordinary shares fell below $1.00 for 30 consecutive business days. The company has been granted an initial compliance period of 180 calendar days, ending on November 9, 2026, to regain compliance. To achieve this, the closing bid price must reach at least $1.00 for a minimum of 10 consecutive business days. If compliance is not met by the deadline, Enlivex may be eligible for an additional 180-day period, provided it meets other listing standards and potentially implements a reverse stock split. The notice has no immediate impact on the company's listing or business operations. Enlivex continues to advance its clinical-stage immunotherapy, Allocetraβ’, while managing a prediction markets treasury strategy involving the RAIN token.